- Efficacy and Safety of Tenofovir-Based Rescue Therapy for Chronic Hepatitis B Patients with Previous Nucleo(s/t)ide Treatment Failure
-
Lee CI, Kwon SY, Kim JH, Choe WH, Lee CH, Yoon EL, Yeon JE, Byun KS, Kim YS, Kim JH
- KMID: 1774530
- Gut Liver.
- 2014 Jan;8(1):64-69.
BACKGROUND/AIMS: We investigated the efficacy and safety of tenofovir disoproxil fumarate (TDF)-based treatment in chronic hepatitis B (CHB) patients who failed previous antiviral therapies. METHODS: Seventeen patients who failed to achieve... -
- CITED
-
- Close
- SHARE
-
- Close
- Development of Clevudine Resistance after Switching from Lamivudine in a Patient with Chronic Hepatitis B
-
Koh KH, Kang CJ, Kim DH, Choi YW, Kim MJ, Cheong JY, Cho SW
- KMID: 783106
- Korean J Gastroenterol.
- 2008 Nov;52(5):325-328.
Clevudine is a nucleoside analog of the unnatural beta-L configuration which has potent antiviral activity against hepatitis B virus (HBV). Clevudine is expected to have similar pattern of resistance profile... -
- CITED
-
- Close
- SHARE
-
- Close
- The Prophylactic Use of Lamivudine Can Maintain Dose-Intensity of Adriamycin in Hepatitis-B Surface Antigen (HBs Ag)-positive Patients with Non-Hodgkin's Lymphoma Who Receive Cytotoxic Chemotherapy
-
Lee GW, Ryu MH, Lee JL, Oh S, Kim E, Lee JH, Kim SB, Kim SW, Suh C, Lee KH, Kim WK, Lee JS, Kang YK
- KMID: 1086742
- J Korean Med Sci.
- 2003 Dec;18(6):849-854.
- doi: 10.3346/jkms.2003.18.6.849
We investigated the effectiveness of lamivudine to prevent hepatitis flare up due to reactivation of hepatitis-B virus (HBV) in hepatitis-B surface antigen (HBsAg)-positive patients with Non-Hodgkin's lymphoma (NHL) during cytotoxic... -
- CITED
-
- Close
- SHARE
-
- Close
- The Clinical Meaning of the Emergence of Viral Breakthrough during Lamivudine Treatment in Patients with Hepatitis B Virus Related Chronic Liver Disease
-
Park CB, Lim HJ, Yun BC, Lee SU, Han BH
- KMID: 760538
- Korean J Hepatol.
- 2004 Jun;10(2):108-116.
BACKGROUND/AIMS: Viral breakthrough has been considered a major limitation of lamivudine in the treatment of hepatitis B virus related chronic liver disease. Its clinical meaning has not been thoroughly... -
- CITED
-
- Close
- SHARE
-
- Close
- Predictive Factors and Clinical Outcome of Viral Breakthrough during Lamivudine Treatment for Chronic Hepatitis B Infection
-
Park NH, Shin JW, Park JH, Bang SJ, Kim DH, Joo KR, Kim DH
- KMID: 1085302
- Korean J Hepatol.
- 2003 Dec;9(4):293-303.
BACKGROUND/AIMS: Long-term treatment with lamivudine causes breakthrough, but the clinical course after lamivudine breakthrough is not well known. The aims of this study were to evaluate the clinical course... -
- CITED
-
- Close
- SHARE
-
- Close
- Detection of YMDD Motif Mutants by Oligonucleotide Chips in Lamivudine-Untreated Patients with Chronic Hepatitis B Virus Infection
-
Heo J, Cho M, Kim HH, Shin YM, Jang HJ, Park HK, Kim CM, Kim GH, Kang DH, Song GA, Yang US
- KMID: 2157683
- J Korean Med Sci.
- 2004 Aug;19(4):541-546.
- doi: 10.3346/jkms.2004.19.4.541
Lamivudine, a nucleoside analogue, has been used widely as an effective antiviral agent for the treatment of patients with chronic hepatitis B virus (HBV) infection. However, the YMDD motif mutation... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical Outcomes after Discontinuation of Lamivudine in Chronic Hepatitis B Patients with Lamivudine Resistant HBV Mutant
-
Kim JK, Hwang SG, Park H, Choi HY, Cho HJ, Ko KH, Hong SP, Park PW, Kim NK, Rim KS
- KMID: 760605
- Korean J Hepatol.
- 2005 Sep;11(3):227-242.
BACKGROUND/AIMS: The therapeutic strategies of applying adefovir for treating lamivudine resistant HBV mutants are controversial. Thus, we observed the clinical outcomes after discontinuation of lamivudine to establish the timing... -
- CITED
-
- Close
- SHARE
-
- Close
